Outcomes Prediction in Complex High-Risk Indicated Percutaneous Coronary Interventions in the Older Patients.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 10 2023
Historique:
received: 10 06 2023
revised: 27 07 2023
accepted: 31 07 2023
medline: 22 9 2023
pubmed: 5 9 2023
entrez: 4 9 2023
Statut: ppublish

Résumé

Complex high-risk indicated percutaneous coronary intervention (CHIP-PCI) is a poorly defined concept, which has not been validated in an older population before. This study aimed to evaluate the predictive value of the CHIP-PCI score in a large cohort of elderly patients and to identify potential further risk factors. This is a pooled analysis of 3 registries that included patients aged ≥75 years who underwent percutaneous coronary intervention from 2012 to 2019: the multicenter prospective EPIC05-Sierra 75 study, the multicenter retrospective PACO-PCI (EPIC-15) registry, and the single-center, prospective Elderly-HCD registry. A total of 2,725 patients with a mean age of 81 ± 4 years were included in the study; 269 patients (10%) met the primary end point of 1-year major adverse cardiac and cerebrovascular events (MACCEs), and 51 patients (2%) had in-hospital MACCEs. Of the 12 investigated original CHIP-PCI score variables, 5 were independent predictors: previous myocardial infarction, left ventricular ejection fraction <30%, chronic kidney disease, left main coronary artery percutaneous coronary intervention, and nonradial access. Furthermore, diabetes mellitus, anemia, and severe calcification showed to be significant predictors of MACCEs. The additional variables improved the discriminatory value of the CHIP-PCI score for 1-year MACCEs (modified CHIP-PCI score: area under the curve [AUC] 0.647 vs original CHIP-PCI score: AUC 0.598, p = 0.02) and in-hospital MACCEs (AUC 0.729 vs 0.657, p = 0.003, respectively). In conclusion, the CHIP-PCI score retains its prognostic value in older patients for in-hospital MACCEs; however, it is of limited value at 1-year follow-up. The modified CHIP-PCI score, including the 5 patient-related and 3 procedure-related factors, significantly improved its discriminatory potential.

Identifiants

pubmed: 37666020
pii: S0002-9149(23)00736-1
doi: 10.1016/j.amjcard.2023.07.166
pii:
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

465-472

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors have no competing interests to declare.

Auteurs

Alexander Marschall (A)

Department of Cardiology, Central Defense Hospital Gómez Ulla, Madrid, Spain; University of Alcalá, Madrid, Spain. Electronic address: marschall.alexander@gmx.de.

David Martí Sánchez (D)

Department of Cardiology, Central Defense Hospital Gómez Ulla, Madrid, Spain; University of Alcalá, Madrid, Spain.

José Luis Ferreiro (JL)

Department of Cardiology, Bellvitge University Hospital, CIBER-CV, L'Hospitalet de Llobregat, Barcelona, Spain.

Ramon Lopez Palop (R)

Department of Cardiology, San Juan University Hospital, Alicante, Spain.

Soledad Ojeda (S)

Department of Cardiology, Reina Sofia University Hospital, University of Córdoba, Maimonides Institute for Research in Biomedicine of Córdoba (IMIBIC), Cordoba, Spain.

Pablo Avanzas (P)

Department of Cardiology, Central de Asturias University Hospital, Department of Medicine, University of Oviedo, Oviedo, Spain; Health Research Institute of Asturias, ISPA, Oviedo, Spain.

Jesus M Jimenez Mazuecos (JM)

Department of Cardiology, Albacete University Hospital, Albacete, Spain.

Pilar Carrillo Sáez (P)

Department of Cardiology, San Juan University Hospital, Alicante, Spain.

Alejandro Gutierrez-Barrios (A)

Department of Cardiology, Puerta del Mar University Hospital, Cadiz, Spain.

Jose M de la Torre Hernandez (JM)

Department of Cardiology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH